GlycoSyn is a business unit of Callaghan Innovation (formerly Industrial Resrach Limited) that specialises in high quality, fast-paced drug development and prototype scale-up manufacture of complex drug candidates for its clients. Essentially, it is in the business of taking chemistry ‘off the bench and into people’.GlycoSyn is a unique and self-sustaining capability in Australasia and one that has delivered enormous value to its clients, helping them move their drugs and products towards commercial success. GlycoSyn is proud to have been, and to be, involved in developing therapeutics that target numerous debilitating and life-threatening diseases and disorders, some of which have particular relevance to New Zealanders, such as melanoma, gout, neurodegenerative disorders (MS and Parkinsons), psoriasis, cancer, HIV and neuropathic pain.GlycoSyn’s unique area of excellence is conducting difficult science at scale, for the first time, using the combined resources of the wider organisation to manage the enormous technical risks associated with early pharmaceutical API development.